Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples.
The Gastrin-Releasing Peptide Receptor (GRPR) is over-expressed in estrogen receptor (ER) positive breast tumors and related metastatic lymph nodes offering the opportunity of imaging and therapy of luminal tumors. 68Ga-RM2 binding and 18F-FDG binding in tumoral zones were measured and compared usin...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2019-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0210905 |
| _version_ | 1818938887275282432 |
|---|---|
| author | Clément Morgat Romain Schollhammer Gaétan Macgrogan Nicole Barthe Valérie Vélasco Delphine Vimont Anne-Laure Cazeau Philippe Fernandez Elif Hindié |
| author_facet | Clément Morgat Romain Schollhammer Gaétan Macgrogan Nicole Barthe Valérie Vélasco Delphine Vimont Anne-Laure Cazeau Philippe Fernandez Elif Hindié |
| author_sort | Clément Morgat |
| collection | DOAJ |
| description | The Gastrin-Releasing Peptide Receptor (GRPR) is over-expressed in estrogen receptor (ER) positive breast tumors and related metastatic lymph nodes offering the opportunity of imaging and therapy of luminal tumors. 68Ga-RM2 binding and 18F-FDG binding in tumoral zones were measured and compared using tissue micro-imaging with a beta imager on 14 breast cancer samples (10 primaries and 4 associated metastatic lymph nodes). Results were then assessed against ER expression, progesterone receptor (PR) expression, HER2 over-expression or not and Ki-67 expression. GRPR immunohistochemistry (IHC) was also performed on all samples. We also retrospectively compared 68Ga-RM2 and 18F-FDG bindings to 18F-FDG SUVmax on the pre-therapeutic PET/CT examination, if available. 68Ga-RM2 binding was significantly higher in tumors expressing GRPR on IHC than in GRPR-negative tumors (P = 0.022). In ER+ tumors, binding of 68Ga-RM2 was significantly higher than 18F-FDG (P = 0.015). In tumors with low Ki-67, 68Ga-RM2 binding was also significantly increased compared to 18F-FDG (P = 0.029). Overall, the binding of 68Ga-RM2 and 18F-FDG displayed an opposite pattern in tumor samples and 68Ga-RM2 binding was significantly higher in tumors that had low 18F-FDG binding (P = 0.021). This inverse correlation was also documented in the few patients in whom a 18F-FDG PET/CT examination before surgery was available. Findings from this in vitro study suggest that GRPR targeting can be an alternative to 18F-FDG imaging in ER+ breast tumors. Moreover, because GRPR antagonists can also be labeled with lutetium-177 this opens new avenues for targeted radionuclide therapy in the subset of patients with progressive metastatic disease following conventional treatments. |
| first_indexed | 2024-12-20T06:14:59Z |
| format | Article |
| id | doaj.art-677846a9de1342ae8fb76680bad8197f |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-20T06:14:59Z |
| publishDate | 2019-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-677846a9de1342ae8fb76680bad8197f2022-12-21T19:50:34ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01141e021090510.1371/journal.pone.0210905Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples.Clément MorgatRomain SchollhammerGaétan MacgroganNicole BartheValérie VélascoDelphine VimontAnne-Laure CazeauPhilippe FernandezElif HindiéThe Gastrin-Releasing Peptide Receptor (GRPR) is over-expressed in estrogen receptor (ER) positive breast tumors and related metastatic lymph nodes offering the opportunity of imaging and therapy of luminal tumors. 68Ga-RM2 binding and 18F-FDG binding in tumoral zones were measured and compared using tissue micro-imaging with a beta imager on 14 breast cancer samples (10 primaries and 4 associated metastatic lymph nodes). Results were then assessed against ER expression, progesterone receptor (PR) expression, HER2 over-expression or not and Ki-67 expression. GRPR immunohistochemistry (IHC) was also performed on all samples. We also retrospectively compared 68Ga-RM2 and 18F-FDG bindings to 18F-FDG SUVmax on the pre-therapeutic PET/CT examination, if available. 68Ga-RM2 binding was significantly higher in tumors expressing GRPR on IHC than in GRPR-negative tumors (P = 0.022). In ER+ tumors, binding of 68Ga-RM2 was significantly higher than 18F-FDG (P = 0.015). In tumors with low Ki-67, 68Ga-RM2 binding was also significantly increased compared to 18F-FDG (P = 0.029). Overall, the binding of 68Ga-RM2 and 18F-FDG displayed an opposite pattern in tumor samples and 68Ga-RM2 binding was significantly higher in tumors that had low 18F-FDG binding (P = 0.021). This inverse correlation was also documented in the few patients in whom a 18F-FDG PET/CT examination before surgery was available. Findings from this in vitro study suggest that GRPR targeting can be an alternative to 18F-FDG imaging in ER+ breast tumors. Moreover, because GRPR antagonists can also be labeled with lutetium-177 this opens new avenues for targeted radionuclide therapy in the subset of patients with progressive metastatic disease following conventional treatments.https://doi.org/10.1371/journal.pone.0210905 |
| spellingShingle | Clément Morgat Romain Schollhammer Gaétan Macgrogan Nicole Barthe Valérie Vélasco Delphine Vimont Anne-Laure Cazeau Philippe Fernandez Elif Hindié Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples. PLoS ONE |
| title | Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples. |
| title_full | Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples. |
| title_fullStr | Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples. |
| title_full_unstemmed | Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples. |
| title_short | Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples. |
| title_sort | comparison of the binding of the gastrin releasing peptide receptor grp r antagonist 68ga rm2 and 18f fdg in breast cancer samples |
| url | https://doi.org/10.1371/journal.pone.0210905 |
| work_keys_str_mv | AT clementmorgat comparisonofthebindingofthegastrinreleasingpeptidereceptorgrprantagonist68garm2and18ffdginbreastcancersamples AT romainschollhammer comparisonofthebindingofthegastrinreleasingpeptidereceptorgrprantagonist68garm2and18ffdginbreastcancersamples AT gaetanmacgrogan comparisonofthebindingofthegastrinreleasingpeptidereceptorgrprantagonist68garm2and18ffdginbreastcancersamples AT nicolebarthe comparisonofthebindingofthegastrinreleasingpeptidereceptorgrprantagonist68garm2and18ffdginbreastcancersamples AT valerievelasco comparisonofthebindingofthegastrinreleasingpeptidereceptorgrprantagonist68garm2and18ffdginbreastcancersamples AT delphinevimont comparisonofthebindingofthegastrinreleasingpeptidereceptorgrprantagonist68garm2and18ffdginbreastcancersamples AT annelaurecazeau comparisonofthebindingofthegastrinreleasingpeptidereceptorgrprantagonist68garm2and18ffdginbreastcancersamples AT philippefernandez comparisonofthebindingofthegastrinreleasingpeptidereceptorgrprantagonist68garm2and18ffdginbreastcancersamples AT elifhindie comparisonofthebindingofthegastrinreleasingpeptidereceptorgrprantagonist68garm2and18ffdginbreastcancersamples |